Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological …

CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML) blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as target for …

Determining the levels of CD33 expression on the surface of AML cells may have clinical implications. A higher expression intensity of the antigen implies a higher binding of the …

Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and …

Jan 3, 2022 · Most efforts of developing monoclonal antibodies or antibody-drug conjugates (ADCs) for AML have focused on targeting CD33 (cluster of differentiation antigen 33). …

Nov 20, 2009 · CD33 is a sialic acid-binding immunoglobulin-like lectin (Siglec) located on chromosome 19q13.3. It is highly expressed on early multilineage hematopoietic progenitors …

Nov 5, 2024 · Recently chimeric antigen receptor (CAR) T-cell therapy has developed rapidly on lymphoid tumors, but CAR-T cell therapy for AML still remains unsatisfactory. So, we …

On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute …

Jun 13, 2014 · Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 …

Nov 16, 2012 · The treatment for acute myeloid leukemia (AML) has not changed dramatically for the last 20 years. Anti-CD33 monoclonal antibody therapy, the most prominent of which is …